ABT-751 + bevacizumab + capecitabine + irinotecan

This is an investigational multi-drug combination regimen consisting of four agents: - **ABT-751** is an orally bioavailable sulfonamide small molecule that binds to the colchicine-binding site on beta-tubulin, inhibiting microtubule polymerization and disrupting mitosis. It also exhibits antivascular properties by causing endothelial cell retraction and microtubule loss[1][3][6][9]. - **Bevacizumab** is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis in tumors[7][8][10]. - **Capecitabine** is an oral prodrug of 5-fluorouracil, a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. - **Irinotecan** is a topoisomerase I inhibitor that prevents DNA unwinding and replication. This combination was studied in phase 1 clinical trials for advanced colorectal cancer to determine safety, pharmacokinetics, and maximum tolerated dose. The regimen aimed to combine antimitotic effects with antiangiogenic therapy plus cytotoxic chemotherapy. Despite modest efficacy observed in early studies, further development for colorectal cancer was not pursued due to tolerability issues[1].

Other names

CAPIRI